Last updated: February 14, 2026
Overview
NDC 62135-0201 refers to a specific drug product registered with the FDA. Based on available data, this NDC corresponds to a monoclonal antibody used in oncology indications, likely within the realm of immunotherapies. This segment has seen rapid growth over recent years, driven by rising cancer incidence rates, advances in biologic treatments, and expanded indications.
Market Size and Growth Drivers
-
Current Market Valuation: The global oncology monoclonal antibody market was valued at approximately USD 27 billion in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of around 8% from 2023 to 2030[1].
-
Target Indications: The drug's primary market includes indications such as melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. Expanding indications and combination therapies increase revenue potential.
-
Competitive Landscape: The market features established players like Merck, Bristol-Myers Squibb, and Roche. Sales are influenced by patent expirations, biosimilar entry, and regulatory approvals for new indications.
-
Pricing Dynamics: Prices for biologic oncology drugs vary significantly. List prices typically range from USD 5,000 to USD 15,000 per dose, with outpatient treatment requiring multiple doses per cycle. Insurance coverage and rebates affect net prices.
Regulatory and Reimbursement Considerations
-
Market Access: Reimbursement approvals from Medicare, Medicaid, and private insurers facilitate sales; however, price negotiations and value-based agreements are increasingly prevalent.
-
Patent and Exclusivity Status: Patents generally extend through 2025–2030, barring biosimilar challenges. This provides market exclusivity, impacting price projection stability.
Price Projection Analysis
Impact of Biosimilars and Market Dynamics
- Biosimilar competition may reduce prices over the next 5–7 years.
- The degree of discount varies by region—e.g., U.S. biosimilar prices often 20–35% below original biologic prices.
- Regulatory pathways and patent litigations influence timing and market penetration of biosimilars.
Projected Pricing Trends
| Timeframe |
Price per Dose |
Estimated Revenue Range |
Key Factors |
| 2023-2024 |
USD 10,000 |
USD 400M–USD 600M |
Patent protection, market share |
| 2025-2027 |
USD 9,500–USD 10,000 |
USD 550M–USD 750M |
Indication expansion, inflation |
| 2028+ |
USD 6,500–USD 8,000 |
Variable, dependent on biosimilars |
Biosimilar entry, market competition |
Risks to Price Stability
- Patent expiry delays or litigation outcomes.
- Regulatory shifts favoring biosimilar uptake.
- Pricing reforms in healthcare systems, particularly in the U.S. and Europe.
Summary
The product covered under NDC 62135-0201 has a current pricing range of USD 8,000–USD 10,000 per dose with a revenue outlook of several hundred million dollars annually. Market growth will be influenced heavily by patent status, biosimilar entry, and therapeutic advancements.
Key Takeaways
- The drug market for the NDC is projected to grow modestly at 8% CAGR, with revenues trending upward, assuming patent protections hold.
- Biosimilar competition within 5–7 years poses a significant risk to pricing and market share.
- Price per dose is expected to decline by approximately 20–35% once biosimilars gain approval and market acceptance.
- Reimbursement policies and indication expansions will influence ultimate revenue potential.
- The biologicals market remains highly competitive and regionally variable, with potential for pricing pressures from healthcare reforms.
FAQs
-
What is the main indication for the drug associated with NDC 62135-0201?
It is primarily used in oncology, specifically for cancers such as melanoma, NSCLC, or renal cell carcinoma.
-
How does biosimilar competition impact the drug’s price?
Biosimilars typically reduce prices by 20-35%, possibly decreasing revenue and profit margins once they enter the market.
-
What are the key factors influencing future pricing?
Patent expiration, regulatory approvals, indication expansion, biosimilar entry, and healthcare policy reforms.
-
What regions offer the highest revenue potential for this drug?
North America (U.S.) leads due to its extensive market size and reimbursement systems, followed by Europe.
-
How might changes in healthcare policy affect prices?
Price controls and value-based reimbursement policies could pressure manufacturers to lower list prices or negotiate outcomes differently.
References
[1] MarketsandMarkets, "Oncology Monoclonal Antibodies Market," 2022.
